Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

Background/Objectives: Type 2 diabetes (T2D) remission is increasingly attainable, but its implications for long-term microvascular risk remain uncertain. Methods: We critically appraised longitudinal reports relating achieved remission to subsequent kidney, retinal, neurologic, or composite outcomes, distinguishing temporally separated remission–outcome analyses from supportive glycemic trajectory studies with overlapping ascertainment. Evidence was checked through 5 October 2026, with an additional directly relevant CHIA companion report incorporated during revision. Eight reports were appraised (six principal direct longitudinal reports, one supportive trajectory report, and one contextual retinopathy report); overlapping CHIA populations were identified, while Danish participant overlap remains unverified. Heterogeneous exposures and estimands precluded pooling. Results: Across surgical, lifestyle, primary care and pharmacotherapy settings, several studies associated remission with lower subsequent microvascular risk. In the temporally separated CHIA analysis, remission during the first two years was associated with fewer microvascular complications over the following five years (adjusted HR 0.68, 95% CI 0.62–0.74). In Look AHEAD, remission at any assessed visit was associated with lower high-/very-high-risk chronic kidney disease (HR 0.67, 95% CI 0.52–0.87). Trajectory analyses provide complementary but temporally less secure evidence and should not be equated with medication-free remission. Conclusions: Achieved T2D remission is a potentially informative prognostic state; evidence concerning duration is suggestive but definition- and design-dependent. Neither a causal effect of remission itself nor normalization of prior microvascular risk has been established.

Authors

Institutions

Publication Details

Journal
Endocrines
Published
2026-11-12
DOI
https://doi.org/10.3390/endocrines7040074
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

Sílvia Canivell, Josep Montserrat-Capdevila, Pilar Vaqué Castilla
Endocrines
Diabetes Management and Research
article

Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

Sílvia Canivell, Josep Montserrat-Capdevila, Pilar Vaqué Castilla
article en

Abstract

Background/Objectives: Type 2 diabetes (T2D) remission is increasingly attainable, but its implications for long-term microvascular risk remain uncertain. Methods: We critically appraised longitudinal reports relating achieved remission to subsequent kidney, retinal, neurologic, or composite outcomes, distinguishing temporally separated remission–outcome analyses from supportive glycemic trajectory studies with overlapping ascertainment. Evidence was checked through 5 October 2026, with an additional directly relevant CHIA companion report incorporated during revision. Eight reports were appraised (six principal direct longitudinal reports, one supportive trajectory report, and one contextual retinopathy report); overlapping CHIA populations were identified, while Danish participant overlap remains unverified. Heterogeneous exposures and estimands precluded pooling. Results: Across surgical, lifestyle, primary care and pharmacotherapy settings, several studies associated remission with lower subsequent microvascular risk. In the temporally separated CHIA analysis, remission during the first two years was associated with fewer microvascular complications over the following five years (adjusted HR 0.68, 95% CI 0.62–0.74). In Look AHEAD, remission at any assessed visit was associated with lower high-/very-high-risk chronic kidney disease (HR 0.67, 95% CI 0.52–0.87). Trajectory analyses provide complementary but temporally less secure evidence and should not be equated with medication-free remission. Conclusions: Achieved T2D remission is a potentially informative prognostic state; evidence concerning duration is suggestive but definition- and design-dependent. Neither a causal effect of remission itself nor normalization of prior microvascular risk has been established.

EndocrinesVol. 7(4)
Universitat de Lleida (ES), Primary Health Care (QA), Institut Català de la Salut (ES)
Good health and well-being
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon